FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093354857> ?p ?o ?g. }

• W3093354857 endingPage "A1812" @default.
• W3093354857 startingPage "A1810" @default.
• W3093354857 abstract "SESSION TITLE: Obstructive Lung Disease Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 PURPOSE: Dupilumab, a fully human VelocImmune®-derived monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), dupilumab 200/300 mg every 2 weeks vs placebo significantly reduced severe asthma exacerbations and improved pre-bronchodilator forced expiratory volume in 1 second in patients with uncontrolled, moderate-to-severe asthma. Treatment effects were greater in patients with elevated type 2 biomarkers at baseline. Severe exacerbations are mostly managed in an outpatient setting. Reducing the total use of systemic corticosteroids (SCS) is an important goal in the management of asthma due to the increased risk of adverse events associated with use of SCS. This post hoc analysis assessed the effect of dupilumab vs placebo on severe outpatient asthma exacerbations, total number of days on SCS, and cumulative dose of SCS associated with severe outpatient exacerbations in type 2 asthma patients. METHODS: Among the type 2 asthma patients (baseline blood eosinophils ≥ 150 cells/µL or fractional exhaled nitric oxide ≥ 25 ppb) from QUEST, annualized rates of severe outpatient asthma exacerbations, total number of days of SCS use, and average daily and cumulative dose of SCS use associated with severe outpatient asthma exacerbations were compared between dupilumab and placebo; SCS dose is presented as the prednisone equivalent dose. RESULTS: Of 1,515 type 2 asthma patients, annualized severe outpatient asthma exacerbation rate was significantly reduced by 55% with dupilumab 200 mg (estimate [95% CI]: 0.4 [0.3–0.5]) vs placebo (0.8 [0.7–1.0]; P < 0.0001), and by 61% with dupilumab 300 mg (0.4 [0.3–0.5]) vs placebo (1.0 [0.8–1.3]; P < 0.0001). The annualized total number of days of SCS use (95% CI) with dupilumab 200/300 mg was 13.7 (11.7–16.1)/12.4 (10.7–14.5) vs 19.6 (16.6–23.1; P < 0.0013)/22.5 (19.4–26.2; P < 0.0001) with matched placebos, respectively. The average daily SCS dose during an exacerbation (mg, median [Q1–Q3]) was 27.6 (20.0–40.0)/30.0 (20.0–40.0) with dupilumab 200/300 mg vs 30.0 (24.3–40.0)/30.0 (20.0–40.0) with matched placebo (both P > 0.1). The cumulative SCS dose (mg, median [Q1–Q3]) was 280.0 (140.0–520.0)/250.0 (150.0–400.0) with dupilumab 200/300 mg vs 350.0 (190.0–695.0)/350.0 (180.0–760.0) with matched placebos (both P < 0.05). CONCLUSIONS: Dupilumab patients had significantly lower annualized severe outpatient asthma exacerbation rates, and lower total number of days of SCS use and cumulative dose of SCS associated with severe outpatient asthma exacerbations. CLINICAL IMPLICATIONS: Dupilumab may benefit asthma patients with elevated type 2 biomarkers by reducing the total number of days on SCS, as well as cumulative SCS dose. DISCLOSURES: Advisory Committee Member relationship with Sanofi-Genzyme Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Sanofi-Genzyme Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Sanofi-Genzyme Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Travel Advisory Committee Member relationship with Regeneron Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Regeneron Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Regeneron Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Travel Advisory Committee Member relationship with AstraZeneca Please note: $20001 - $100000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Consulting fee Advisory Committee Member relationship with AstraZeneca Please note: $20001 - $100000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Grant/Research Support Speaker/Speaker's Bureau relationship with AstraZeneca Please note: $20001 - $100000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with AstraZeneca Please note: $20001 - $100000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Travel Advisory Committee Member relationship with Novartis Please note: $5001 - $20000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Consulting fee Advisory Committee Member relationship with Novartis Please note: $5001 - $20000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Consulting fee Removed 05/25/2020 by Giorgio Walter Canonica, source=Web Response Advisory Committee Member relationship with Novartis Please note: $5001 - $20000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Grant/Research Support Speaker/Speaker's Bureau relationship with Novartis Please note: $5001 - $20000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Novartis Please note: $5001 - $20000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Travel Advisory Committee Member relationship with GSK Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with GSK Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with GSK Please note: $1001 - $5000 Added 05/25/2020 by Giorgio Walter Canonica, source=Web Response, value=Travel Author relationship with Elsevier Please note: $1-$1000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Royalty Consultant relationship with VIDA Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Consulting fee Principal Investigator relationship with Novartis Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Consultant relationship with Novartis Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Consulting fee Principal Investigator relationship with Chiesi Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Principal Investigator relationship with AstraZeneca Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Speaker/Speaker's Bureau relationship with AstraZeneca Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Honoraria Principal Investigator relationship with ALA Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Principal Investigator relationship with Sanofi-Aventis Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Consultant relationship with Sanofi-Aventis Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Consulting fee Speaker/Speaker's Bureau relationship with Sanofi-Aventis Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Regeneron Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Teva Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Honoraria Consultant relationship with Teva Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Consulting fee Principal Investigator relationship with GSK Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Speaker/Speaker's Bureau relationship with GSK Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Honoraria Speaker/Speaker's Bureau relationship with Genentech Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Honoraria Consultant relationship with Genentech Please note: $5001 - $20000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Consulting fee Principal Investigator relationship with Pulmatrix Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Principal Investigator relationship with Shionogi Please note: $20001 - $100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Principal Investigator relationship with NIH Please note: >$100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Principal Investigator relationship with PCORI Please note: >$100000 Added 05/25/2020 by Mario Castro, source=Web Response, value=Grant/Research Support Employee relationship with Regeneron Pharmaceuticals Inc. Please note: >$100000 Added 05/27/2020 by Siddhesh Kamat, source=Web Response, value=Salary Employee relationship with Sanofi Please note: $20001 - $100000 Added 04/29/2020 by Asif Khan, source=Web Response, value=Salary Employee relationship with SANOFI Please note: >$100000 Added 05/27/2020 by Asif Khan, source=Web Response, value=Salary Employee relationship with Sanofi Please note: $20001 - $100000 Added 05/27/2020 by Jerome Msihid, source=Web Response, value=Salary Stock holder relationship with Sanofi Please note: $20001 - $100000 Added 05/27/2020 by Jerome Msihid, source=Web Response, value=Shares Employee relationship with Regeneron Pharmaceuticals Inc. Please note: >$100000 Added 05/26/2020 by Benjamin Ortiz, source=Web Response, value=Salary Employee relationship with Sanofi Genzyme Please note: $20001 - $100000 Added 05/28/2020 by Nami Pandit-Abid, source=Web Response, value=Salary Removed 05/28/2020 by Nami Pandit-Abid, source=Web Response Employee relationship with Sanofi Genzyme Please note: >$100000 Added 05/28/2020 by Nami Pandit-Abid, source=Web Response, value=Salary Removed 05/28/2020 by Nami Pandit-Abid, source=Web Response Employee relationship with Sanofi Genzyme Please note: >$100000 Added 05/28/2020 by Nami Pandit-Abid, source=Web Response, value=Salary Consultant relationship with AstraZeneca Please note: $5001 - $20000 Added 04/09/2020 by Robert Zeiger, source=Web Response, value=Consulting fee" @default.
• W3093354857 created "2020-10-22" @default.
• W3093354857 creator A5006031044 @default.
• W3093354857 creator A5007512686 @default.
• W3093354857 creator A5019798684 @default.
• W3093354857 creator A5029849168 @default.
• W3093354857 creator A5035441456 @default.
• W3093354857 creator A5039452184 @default.
• W3093354857 creator A5069220861 @default.
• W3093354857 creator A5089685782 @default.
• W3093354857 date "2020-10-01" @default.
• W3093354857 modified "2023-09-25" @default.
• W3093354857 title "DUPILUMAB REDUCES SEVERE OUTPATIENT ASTHMA EXACERBATIONS, CUMULATIVE DOSE, AND TOTAL NUMBER OF DAYS OF SYSTEMIC CORTICOSTEROID USE AMONG PATIENTS WITH MODERATE-TO-SEVERE TYPE-2 ASTHMA" @default.
• W3093354857 doi "https://doi.org/10.1016/j.chest.2020.08.1572" @default.
• W3093354857 hasPublicationYear "2020" @default.
• W3093354857 type Work @default.
• W3093354857 sameAs 3093354857 @default.
• W3093354857 citedByCount "0" @default.
• W3093354857 crossrefType "journal-article" @default.
• W3093354857 hasAuthorship W3093354857A5006031044 @default.
• W3093354857 hasAuthorship W3093354857A5007512686 @default.
• W3093354857 hasAuthorship W3093354857A5019798684 @default.
• W3093354857 hasAuthorship W3093354857A5029849168 @default.
• W3093354857 hasAuthorship W3093354857A5035441456 @default.
• W3093354857 hasAuthorship W3093354857A5039452184 @default.
• W3093354857 hasAuthorship W3093354857A5069220861 @default.
• W3093354857 hasAuthorship W3093354857A5089685782 @default.
• W3093354857 hasBestOaLocation W30933548571 @default.
• W3093354857 hasConcept C126322002 @default.
• W3093354857 hasConcept C151032500 @default.
• W3093354857 hasConcept C187212893 @default.
• W3093354857 hasConcept C2776042228 @default.
• W3093354857 hasConcept C2776804153 @default.
• W3093354857 hasConcept C2779824493 @default.
• W3093354857 hasConcept C2909082789 @default.
• W3093354857 hasConcept C42219234 @default.
• W3093354857 hasConcept C71924100 @default.
• W3093354857 hasConceptScore W3093354857C126322002 @default.
• W3093354857 hasConceptScore W3093354857C151032500 @default.
• W3093354857 hasConceptScore W3093354857C187212893 @default.
• W3093354857 hasConceptScore W3093354857C2776042228 @default.
• W3093354857 hasConceptScore W3093354857C2776804153 @default.
• W3093354857 hasConceptScore W3093354857C2779824493 @default.
• W3093354857 hasConceptScore W3093354857C2909082789 @default.
• W3093354857 hasConceptScore W3093354857C42219234 @default.
• W3093354857 hasConceptScore W3093354857C71924100 @default.
• W3093354857 hasIssue "4" @default.
• W3093354857 hasLocation W30933548571 @default.
• W3093354857 hasOpenAccess W3093354857 @default.
• W3093354857 hasPrimaryLocation W30933548571 @default.
• W3093354857 hasRelatedWork W2607349441 @default.
• W3093354857 hasRelatedWork W2766363313 @default.
• W3093354857 hasRelatedWork W2944657847 @default.
• W3093354857 hasRelatedWork W2981190950 @default.
• W3093354857 hasRelatedWork W2994997304 @default.
• W3093354857 hasRelatedWork W3093354857 @default.
• W3093354857 hasRelatedWork W3205058914 @default.
• W3093354857 hasRelatedWork W3206421422 @default.
• W3093354857 hasRelatedWork W3207483755 @default.
• W3093354857 hasRelatedWork W4367599627 @default.
• W3093354857 hasVolume "158" @default.
• W3093354857 isParatext "false" @default.
• W3093354857 isRetracted "false" @default.
• W3093354857 magId "3093354857" @default.
• W3093354857 workType "article" @default.